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Background. The efficacy of systemic antineoplastic therapy on recurrent World Health Organization (WHO) grades II and III me-
ningiomas is unclear.
Methods. We performed a retrospective multicenter analysis of serial cranial MRI in patients with recurrent WHO II and III me-
ningiomas treated with antineoplastic systemic therapies. Growth rates for tumor volume and diameter, as well as change rates
for edema size, were calculated for all lesions.
Results. We identified a total of 34 patients (23 atypical, 11 anaplastic meningiomas) with a total of 57 meningioma lesions who
had been treated at 6 European institutions. Systemic therapies included bevacizumab, cytotoxic chemotherapy, somatostatin
analogues, and tyrosine kinase inhibitors. Overall, tumor growth rates decreased during systemic therapy by 51% for tumor diam-
eter and 14% for tumor volume growth rates compared with the period before initiation of systemic therapy. The most pro-
nounced decrease in meningioma growth rates during systemic therapy was evident in patients treated with bevacizumab,
with a reduction of 80% in diameter and 59% in volume growth. Furthermore, a decrease in size of peritumoral edema after ini-
tiation of systemic therapy was exclusively observed in patients treated with bevacizumab (2107%).
Conclusions. Our data indicate that systemic therapy may inhibit growth of recurrent WHO grades II and III meningiomas to some
extent. In our small cohort, bevacizumab had the most pronounced inhibitory effect on tumor growth, as well as some anti-edem-
atous activity. Prospective studies are needed to better define the role of medical therapies in this tumor type.
Keywords: anaplastic meningioma, anti-angiogenesis, atypical meningioma, bevacizumab, chemotherapy.
Meningiomas are the most frequent primary intracranial
tumors in adults according to local and international brain
tumor registries, with an incidence rate of about 30% and a
female predominance, followed by glioblastoma and pituitary
adenoma.1,2 Based on the World Health Organization (WHO)
grade classification, meningiomas are histopathologically
Received 30 April 2015; accepted 4 July 2015
# The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
Neuro-Oncology
Neuro-Oncology 2015; 0, 1–7, doi:10.1093/neuonc/nov183
1 of 7
 Neuro-Oncology Advance Access published September 9, 2015
 at K
U
 Leuven U
niversity Library on February 12, 2016
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
classified and graded into 3 different subgroups: benign menin-
giomas (WHO grade I), atypical meningiomas (WHO grade II),
and anaplastic or malignant meningiomas (WHO grade III).3
The majority of these subgroups are benign, followed by
atypical (up to 20% of all meningiomas) and anaplastic
(about 1%–3% of all meningiomas).1
While benign meningiomas are usually curable by surgery,
atypical and anaplastic meningiomas are characterized by ag-
gressive behavior and a high recurrence rate.3 No accepted
therapy standard exists for meningiomas after exhaustion of
surgical and radiotherapeutic options. A variety of systemic
antineoplastic therapeutic agents, including hydroxyurea,
temozolomide, irinotecan, interferon-alpha, mifepristone,
octreotide analogues, megestrol acetate, bevacizumab, imati-
nib, erlotinib, and gefitinib, have been investigated in small
studies and are being used in the clinical setting.4 – 13 However,
the validity of the available studies is limited by small sample
sizes, retrospective study designs, heterogeneous patient pop-
ulations, lack of control arms, and varying response criteria,
thus rendering the benefit of these drugs unclear.14
In the present study, we aimed to analyze the growth rates
of recurrent WHO grades II and III meningiomas before, dur-
ing, and after treatment with systemic agents in order to pro-
vide novel information on the effect of drug treatment on the
disease course.
Materials and Methods
Patients
Institutional review board approval for this retrospective Euro-
pean multicenter study was obtained from each participating
institution. All participating institutions were asked to provide
radiological as well as predefined epidemiological and clinical
data of the patients using a prepared form (see Supplementary
Material S1).
The inclusion criteria were as follows: (i) patient has histo-
logical diagnosis of WHO grade II or grade III meningioma ac-
cording to 2007 WHO criteria; (ii) patient has received systemic
antineoplastic therapy for tumor recurrence after previous op-
eration and/or radiotherapy; (iii) digital datasets are available of
multiple MR examinations taken before, during, and after the
administration of systemic antineoplastic therapy.
Patient recruitment per institution was as follows: institution
1 (Vienna, n¼ 14), institution 2 (Leuven, n¼ 5), institution 3
(Lille, n¼ 4), institution 4 (Zurich, n¼ 4), institution 5 (Aarau,
n¼ 4), and institution 6 (Essen, n¼ 3). First radiological diagno-
sis of meningioma was made between December 2002 and
December 2013, and systemic antineoplastic therapy com-
menced between October 2005 and October 2013.
Image Acquisition
All patients received an MRI examination with a routine clinical
imaging protocol of the brain. In total, 224 MRI examinations
were included. The mean duration between 2 MRI examina-
tions was 116 days (SD¼ 88 d). Each MRI examination included
at least one T1-weighted sequence without and with contrast
enhancement. In addition, a T2-weighted sequence was per-
formed in 90.6% of all MRI examinations (203/224).
Image Analysis
The anonymized radiological data for participating patients
from all institutions were collected in the form of digital data.
The MR images were qualitatively evaluated at institution 1 on
a PACS (Picture Archiving and Communication System, Centric-
ity, GE Healthcare) workstation by an experienced neuroradiol-
ogist (J.F.) regarding their usability for further postprocessing.
Image postprocessing was performed using open-source soft-
ware (MRIcron).15 Maximum tumor diameter, tumor volume,
and volume of peritumoral edema were measured for each of
the 224 MRI examinations by the same neuroradiologist (J.F.),
blinded to all clinical patient data. T1-weighted postcontrast
images were selected to determine the maximum tumor diam-
eter as well as the tumor volume. The T2-weighted images
were used to depict tumor edema. Maximum tumor diameter
was defined as the biggest diameter of the contrast-enhanced
tumor area measured in axial, coronal, or sagittal image di-
mension. Tumor volume was automatically calculated on the
basis of multiple manually defined regions of interests (ROIs)
including the whole contrast-enhancing tumor area as well
as cystic parts of the tumor in the T1-weighted postcontrast se-
quences. Analogous to the tumor volume, peritumoral edema
was determined using multiple ROIs, including the peritumoral
hyperintense signal alterations in T2-weighted images, exclud-
ing contrast-enhancing tumor areas.
Statistical Analysis
Resulting measurements from tumor volume, maximum tumor
diameter, and the volume of peritumoral edema were submit-
ted for further analysis. All lesions were subdivided into 3 differ-
ent subgroups related to patients’ therapy status. The subgroup
“pretherapeutic” represented all meningiomas before systemic
therapy; the subgroup “therapeutic” included a pretherapeutic
baseline measurement within 4 weeks before the start of
systemic therapy, all measurements during systemic therapy,
and the first measurement after systemic therapy if it was
performed within 4 weeks after the completion of systemic
therapy. All measurements after the systemic therapy are
summarized in the “posttherapeutic” subgroup.
Measurements of maximum tumor diameter, maximum
tumor volume, and maximum peritumoral edema volume of
every lesion were used to derive gradients of decrease and in-
crease, which are specified as average growth rates for tumor
volume and diameter and average change rates for edemas
throughout the manuscript. Growth and change rates were de-
fined as the decrease or increase in tumor diameter, tumor vol-
ume, or peritumoral edema volume over a period of time (t),
expressed as cm/t and cm3/t, respectively. The time period
was determined by the average MR follow-up interval of the le-
sions. Pearson correlation coefficient was used to assess the re-
lation between the calculated growth rates of tumor diameter
and tumor volume.
A positive growth rate indicated an increase of tumor diam-
eter, tumor volume, or edema volume, while a negative growth
rate reflected a decrease of the different measurements. A
growth rate of zero indicated no change in volume or diameter.
Statistical Package for the Social Sciences (SPSS) version 20.0
was used for descriptive statistics of the cohorts. Visualizations
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were performed in MatLab (7.14.0, Release 2012a; Mathworks).
Testing for group differences between therapies was not uti-
lized because of the small and unbalanced sample size.
Results
Patient Characteristics
We identified 34 patients with a total of 57 meningioma lesions
that had been treated at 6 European institutions. Twenty-three
patients (68%) had atypical meningiomas and 11 patients
(32%) had anaplastic meningiomas. Systemic therapies includ-
ed bevacizumab (n¼ 5), cytotoxic chemotherapy (n¼ 9), soma-
tostatin analogues (n¼ 9), and tyrosine kinase inhibitors (n¼ 7).
In 4 patients, radiological data during systemic therapy were not
available, therefore these patients were included only in the
“pretherapeutic” subgroup. Detailed patients’ baseline charac-
teristics and the types of administered systemic therapies are
given in Supplementary Material S2 and S3.
Thirty-two meningiomas were analyzable in the prethera-
peutic time window, 37 meningiomas in the therapeutic time
window, and 26 in the posttherapeutic time window. The mean
time period was 140 days (SD¼ 124 d, range¼ 13–637; mean
number of MR examinations¼ 3.65, range¼ 2–6) for all prether-
apeutic MR examinations; 78 days (SD¼ 23, range¼ 41–156;
mean number of MR examination¼ 3.13, range¼ 2 – 7) for
systemic therapy; and 142 days (SD¼ 79, range¼ 21 –334;
mean number of MR examinations¼ 3.92, range¼ 2–7) for
all posttherapeutic MR examinations.
Analysis of Solid Tumor Lesions
Measurements of maximum tumor diameter and tumor vol-
ume were represented as average growth rates and further
subdivided into values for pretherapeutic lesions (n¼ 32), ther-
apeutic lesions (n¼ 37), and posttherapeutic lesions (n¼ 26).
Overall, diameter and volume growth rate values of the
tumor lesions showed a high correlation in total (Pearson
correlation coefficient r¼ 0.722; P¼ 1.4903×10216), in
the pretherapeutic (r¼ 0.794; P¼ 5.8995×1028), therapeutic
(r¼ 0.52; P¼ 0.001), and posttherapeutic (r¼ 0.892; P¼
9.144×10210) subgroups.
Table 1 and Figs 1A and B and 2A and B detail the tumor
growth rates per time window and type of administered thera-
py. Overall, the mean tumor growth rates decreased by 51% for
tumor diameter and 14% for tumor volume in the therapeutic
period compared with the pretherapeutic period. Comparing
the growth rates between the different therapy types, we
observed the highest decrease of growth rate from the prether-
apeutic to the therapeutic period in patients treated with bev-
acizumab (diameter: 280%, volume: 259%), followed by the
subgroup of patients treated with chemotherapy (diameter:
254%, volume: +7%) and tyrosine kinase inhibitors (diameter:
240%, volume: 229%). Interestingly, in the posttherapeutic
period, patients treated with bevacizumab showed the highest
increase, with 200% in growth rates with regard to tumorous
lesion diameter and the second highest increase in terms of
tumor volume, with 50% in comparison with the therapeutic
period. The lowest growth rates in the posttherapeutic period
were observed with tyrosine kinase inhibitors, with regard to
both tumor diameter and tumor volume.
Furthermore, tumor growth rates were subdivided, regard-
ing tumor histology, into tumor diameter and volume growth
rates of WHO grades II and III meningiomas per time window
in Table 2. In the pretherapeutic as well as the therapeutic pe-
riod, tumor growth rates (both diameter and volume) of the dif-
ferent histological meningioma subtypes were approximately
balanced, whereas in the posttherapeutic period, tumor growth
rates were considerably lower in atypical meningiomas than in
anaplastic meningiomas.
A further analysis using Response Evaluation Criteria In Solid
Tumors during treatment with systemic therapy (therapeutic
period) revealed stable disease (defined as ≤30% decrease or
≥20% increase in the maximum tumor diameter) in 25
patients and progressive disease (defined as ≥20% increase
in the maximum tumor diameter) in 12 cases as the best
responses during the treatment periods (see Supplementary
Material S4).
Table 1. Growth rates of all solid tumor lesions
Time Window Systemic Therapy Analyzable
Meningiomas, n
Length of Time
Window, days
Change in Diameter
per Time [cm/time]
Change in Volume
per Time [cm3/time]
Mean SD Mean SD Mean SD
Pretherapeutic All 32 139.98 123.61 0.0100 0.0193 0.0488 0.9431
Therapeutic All 37 78.00 22.58 0.0049 0.0080 0.0420 0.0700
Bevacizumab 9 75.56 7.50 0.0020 0.0080 0.0200 0.0430
Chemotherapy 13 82.31 27.51 0.0046 0.0070 0.0523 0.0863
Somatostatin analogues 4 73.25 14.84 0.0100 0.0000 0.0825 0.0860
Tyrosine kinase inhibitor 11 76.64 27.84 0.0060 0.0120 0.0345 0.0624
Posttherapeutic All 26 141.92 78.52 0.0040 0.0090 0.0258 0.0569
Bevacizumab 5 78.40 4.66 0.0060 0.0134 0.0300 0.0670
Chemotherapy 7 98.53 47.48 0.0040 0.0050 0.0186 0.0240
Somatostatin analogues 11 194.98 87.01 0.0030 0.0090 0.0336 0.0760
Tyrosine kinase inhibitor 3 154.50 0.00 0.0000 0.0000 0.0067 0.0060
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Analysis of Peritumoral Edema
Changes of peritumoral edema were defined as the change
rates of maximum peritumoral edema volume over a period
of time and were evaluated during the pretherapeutic period
in 12 meningiomas, during the therapeutic period in 36 menin-
giomas, and during the posttherapeutic period in 25 meningio-
mas. In the overall cohort, mean change rates of peritumoral
edema volume were positive in all time periods and were high-
est in the pretherapeutic and lowest in the posttherapeutic
period (Table 3, Fig. 1C). Comparing edema volume change
rates between the patient populations treated with different
therapies, a decrease in edema volume was evident exclusively
in the therapeutic period in patients treated with bevacizumab,
with a change rate of 20.007 cm3/t (SD¼ 0.0210) (resulting
in a reduction of peritumoral edema change rate of 107%
compared with the pretherapeutic period), whereas all other in-
cluded therapies together showed an average increase in peri-
tumoral edema change rate of 0.1070 cm3/t (SD¼ 0.2350)
(resulting in an increase of peritumoral edema change rate of
7% compared with the pretherapeutic period). The remarkable
effect of bevacizumab on peritumoral edema change rates dur-
ing the therapy period in comparison with all other included
systemic therapies is visualized in Fig. 2C.
A reduction in peritumoral edema volume change rate by
29% compared with the pretherapeutic period was detected
during the application of chemotherapy, while in the case of
somatostatin analogues and tyrosine kinase inhibitors, peritu-
moral edema showed an increase in change rates of 95% and
15%, respectively. After the termination of systemic therapy, no
change of peritumoral edema volume was determined in the
chemotherapy subgroup. The second lowest peritumoral
edema change rate after termination of systemic therapy
was determined in the bevacizumab cohort, whereas patients
who were treated with somatostatin analogues or tyrosine ki-
nase inhibitor showed the highest posttherapeutic peritumoral
edema change rates.
Fig. 1. Visualization of change gradients of (A) tumor diameter, (B) tumor volume, and (C) peritumoral edema before (continuous lines), during
(dashed lines), and after (dotted lines) systemic therapy. The slopes describe the direction (decrease or increase) and steepness (intensity) for the 3
groups, respectively. A very steep line therefore indicates a rapid increase. As clearly visible, growth velocity for all 3 measures (diameter growth
rate, volume growth rate, edema change rate) degrades from before to after therapy.
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Moreover, peritumoral edema change rates were evaluated
with regard to the different histological meningioma subgroups
in Table 2. Remarkably, peritumoral edema volume change
rates were lower in atypical meningiomas in the pretherapeutic
as well as in the therapeutic period than in anaplastic
meningiomas, while there was almost no difference in the
posttherapeutic period. Moreover, during systemic therapy,
atypical meningiomas showed increased peritumoral edema
change rates, while the peritumoral edema in anaplastic me-
ningiomas decreased in comparison with the pretherapeutic
period. After systemic therapy, peritumoral edema volumes
showed the lowest change rates in atypical as well as
Fig. 2. Growth rates expressed as lesion (A) diameter and (B) volume shown for different systemic therapies (black lines¼ bevacizumab; dotted
lines¼ chemotherapy; grey lines¼ somatostatin analogues; dashed lines¼ tyrosine kinase inhibitor) in the therapeutic and posttherapeutic
periods. Since the growth rate of lesion diameter after administration of tyrosine kinase inhibitor was zero, no dashed line is shown in this
section. Column C represents the changes of peritumoral edema volumes shown for bevacizumab (black line) versus all chemotherapies,
somatostatin analogues, and tyrosine kinase inhibitors pooled (dashed line) during therapy application. The slopes describe the direction
(decrease or increase) and steepness (intensity) for the 3 groups, respectively. A very steep line therefore indicates a rapid increase.
Table 2. Growth rates of solid tumor lesions and change rates of peritumoral edema by WHO grades II and III
Time Window WHO Grade Analyzable
Meningiomas, n
Length of Time
Window, days
Change in Diameter
per Time [cm/time]
Change in Volume per
Time [cm3/time]
Mean SD Mean SD Mean SD
Pretherapeutic Lesion II 17 188.35 146.39 0.0100 0.0240 0.0420 0.0970
III 15 85.18 57.31 0.0100 0.0130 0.0560 0.0940
Edema II 6 159.680 42.250 0.0317 0.0440
III 6 48.360 57.470 0.1680 0.3390
Therapeutic Lesion II 24 81.29 20.84 0.0042 0.0070 0.0420 0.0670
III 13 71.92 25.19 0.0062 0.0112 0.0423 0.0780
Edema II 23 81.610 21.260 0.0661 0.1580
III 13 71.920 25.190 0.1008 0.2840
Post therapeutic Lesion II 20 155.38 81.27 0.0030 0.0070 0.0180 0.0350
III 6 97.07 50.99 0.0070 0.0121 0.0517 0.1025
Edema II 19 159.770 81.000 0.0247 0.0413
III 6 97.070 50.990 0.0233 0.0367
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anaplastic meningiomas in comparison with the pretherapeutic
and therapeutic periods.
Discussion
The role of systemic therapies in recurrent WHO grades II and
III meningiomas is ill-defined. So far, medical therapy of these
tumors has been evaluated only in case reports, retrospective
patient series, and small and uncontrolled prospective studies.
The 6-month progression-free survival (PFS-6) rates reported
among these studies show a high variability, ranging from 3%
to 64.3%. A recent systematic analysis proposed a PFS-6 rate of
26% as the benchmark for historical comparisons.14 Consider-
ing this benchmark, hydroxyurea, octreotide analogues, gefiti-
nib, and erlotinib were deemed ineffective,4,13,16 while
anti-angiogenic drugs, including bevacizumab, vatalanib, and
sunitinib showed potential activity, with PFS-6 rates of 37.5%
to 64.3%.11,14,17 – 19 Interestingly, our data support a potential
role of anti-angiogenic treatment in recurrent WHO grades II
and III meningioma, as the most pronounced decrease of
tumor growth rates was observed in patients put on bevacizu-
mab therapy. Of note, however, we observed evidence for
drug-induced tumor growth inhibition also for the other types
of systemic therapies analyzed in our series, although to a con-
siderably smaller extent than for bevacizumab. The activity of
bevacizumab or other anti-angiogenic agents targeting the
vascular endothelial growth factor (VEGF) pathway in WHO
grades II and III meningioma seems rational from a pathobio-
logical point of view, as prominent expression of VEGF and its
receptors as well as neo-angiogenesis have repeatedly been
shown in this tumor type.20,21 Ongoing prospective studies
(NCT00972335, NCT01125046) will provide more data on the
role of bevacizumab for aggressive meningiomas. A point of
caution, however, may be deduced from our observation of in-
creased growth rates after cessation of bevacizumab therapy
that were not noted in patients treated with other drugs. “Re-
bound effects” characterized by more malignant behavior after
termination of bevacizumab therapy have been described for
vestibular schwannoma, and further studies should address
this issue also in meningioma.22
Bevacizumab has shown considerable and clinically relevant
anti-edematous properties in gliomas and brain metastases.
Our data indicate that this effect is also relevant in meningioma
patients, as we saw shrinking of peritumoral edema volumes
exclusively in patients under bevacizumab treatment. This
finding is well in line with reports showing an important role
for VEGF in edema formation in meningioma.23 – 25 Thus, beva-
cizumab treatment may be of particular clinical benefit in
meningioma patients with symptomatic peritumoral edema
and may help to decrease symptomatic burden and corticoste-
roid need.
Our study has several limitations; despite the multicenter
approach, we were able to assemble only a relatively small pa-
tient cohort in this rare tumor type. In a number of cases we
were unfortunately not able to retrospectively retrieve the neu-
roimages (or only neuroimages of insufficient quality), because
they were done at external institutions. To overcome the indi-
vidual bias of heterogenic time periods between the MR
follow-up examinations at each center, growth rates, which
were defined as maximum change in tumor diameter or
tumor volume over a period of time, were used. Another limita-
tion is the heterogeneity of administered treatments and the
retrospective mode of data analysis. Overall, it is important to
note that our analyses are strictly descriptive and need to be
carefully interpreted and validated by larger, optimally prospec-
tive investigations. In general, the lack of reductions in tumor
sizes seen with systemic agents suggests that response rate
is not an optimal endpoint for clinical trials with medical ther-
apies in meningiomas but that progression-free survival times
or the change in growth rates may be more appropriate end-
points. In any case, our study emphasizes the need for stand-
ardization of imaging protocols and clinical management
algorithms in aggressive meningioma patients to overcome
the wide variation in clinical practice.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal
online (http://neuro-oncology.oxfordjournals.org/).
Table 3. Changes of peritumoral edema volume
Time Window Systemic Therapy Analyzable
Meningiomas, n
Length of Time
Window, days
Change in Volume per
Time [cm3/time]
Mean SD Mean SD
Pretherapeutic All 12 104.02 75.45 0.1000 0.2410
Therapeutic All 36 78.11 22.89 0.0780 0.0349
Bevacizumab 9 75.55 7.50 20.0070 0.0210
Chemotherapy 12 83.00 28.62 0.0710 0.1470
Somatostatin analogues 4 73.25 14.84 0.1950 0.2700
Tyrosine kinase inhibitor 11 76.64 27.84 0.1145 0.3060
Posttherapeutic All 25 144.72 78.80 0.0244 0.0390
Bevacizumab 5 78.40 4.66 0.0080 0.0180
Chemotherapy 6 102.95 50.41 0.0000 0.0000
Somatostatin analogues 11 194.00 87.00 0.0380 0.0350
Tyrosine kinase inhibitor 3 154.50 0.00 0.0500 0.0860
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